Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis

Clinical Rheumatology

Volumn 35, Issue 2, 2016, Pages 441-446

  Özçakar, Z Birsin ^a   Özdel, Semanur ^a   Yılmaz, Songül ^a   Kurt Şükür, E Didem ^a   Ekim, Mesiha ^a   Yalçınkaya, Fatoş ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Amyloidosis; Anakinra; Canakinumab; Familial Mediterranean fever; Treatment

Indexed keywords

CANAKINUMAB; COLCHICINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY;

AMYLOIDOSIS; ARTICLE; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG DOSE REDUCTION; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENE MUTATION; HUMAN; MALE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; COMPLICATION; DRUG RESISTANCE; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; CHILD; COLCHICINE; DRUG RESISTANCE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84958259080     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2772-2     Document Type: Article

References (30)

1. Lidar M, Livneh A (2007) Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med 65:318–324
2. Mamou H, Cattan R (1952) La maladie periodique (sur 14 cas personnels dont 8 compliques de nephropathies). Sem Hop Paris 28:1062–1070
3. Goldfinger SE (1972) Colchicine for familial Mediterranean fever. N Engl J Med 287:1302
4. Özkan E, Okur Ö, Ekmekçi A, Özcan R, Tağ T (1972) A new approach to the treatment of periodic fever. Med Bull İstanbul 5:44–49
5. Touitou I, Sarkisian T, Medlej-Hashim M et al (2007) Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 56:1706–1712
6. Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and review of the literature. Semin Arthritis Rheum 41:265–271
7. Akgul S, Kılıç E, Kılıç G, Özgöçmen S (2013) Efficacy and safety of biological treatments in familial Mediterranean fever. Am J Med Sci 346:137–141
8. Ozçakar ZB, Yüksel S, Ekim M, Yalçınkaya F (2012) Infliximab therapy for familial mediterranean fever-related amyloidosis: case series with long term follow-up. Clin Rheumatol 31:1267–1271
9. Grattagliano I, Bonfrate L, Ruggiero V, Scaccianoce G, Palasciano G, Portincasa P (2014) Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther 95:89–97
10. Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T (2007) Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 146:825–826
11. Mitroulis I, Papadopoulos VP, Konstantinidis T, Ritis K (2008) Anakinra suppresses familial Mediterranean fever crises in a colchicine resistant patient. Neth J Med 66:489–491
12. Stojanovic KS, Delmas Y, Torres PU et al (2012) Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant 27:1898–1901
13. Moser C, Pohl G, Haslinger I et al (2009) Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transplant 24:676–678
14. Alpay N, Şumnu A, Çalışkan Y, Yazıcı H, Türkmen A, Gül A (2012) Efficacy of anakinra treatment in a patient with colchicine resistant familial Mediterranean fever. Rheumatol Int 32:3277–3279
15. Yalçınkaya F, Özen S, Özçakar ZB et al (2009) A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 48:395–398
16. Aksentijevich I, Torosyan Y, Samuels J et al (1999) Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the ashkenazi jewish population. Am J Hum Genet 64:949–962
17. Yilmaz E, Ozen S, Balci B et al (2001) Mutation frequency of familial Mediterranean fever and evidence for a high carrier rate in the turkish population. Eur J Hum Genet 9:553–555
18. The International FMF Consortium (1997) Ancient missense mutations in a new member of the roret gene family are likely to cause familial Mediterranean fever. Cell 90:797–807
19. The French FMF Consortium (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17:25–31
20. Chae JJ, Aksentijevich I, Kastner DL (2009) Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 146:467–478
21. Urieli-Shoval S, Linke RP, Matzner Y (2000) Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7:64–69
22. Özdoğan H, Arısoy N, Kasapçopur Ö et al (1997) Vasculitis in familial Mediterranean fever. J Rheumatol 24:323–327
23. Tekin M, Yalçınkaya F, Tümer N et al (1999) Familial Mediterranean fever—renal involvement by diseases other than amyloid. Nephrol Dial Transplant 14:475–479
24. Livneh A, Langevitz P, Zemer D et al (1996) The changing face of familial Mediterranean fever. Semin Arthritis Rheum 26:612–627
25. Ben-Chetrit E, Levy M (1991) Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 20:241–246
26. Zemer D, Livneh A, Danon YL, Pras M, Sohar E (1991) Long term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 34:973–977
27. Lidar M, Yonath H, Shechter N et al (2012) Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 12:72–76
28. Ozcakar ZB, Elhan AH, Yalcinkaya F (2014) Can colchicine response be predicted in familial Mediterranean fever patients. Rheumatology (Oxford). doi:10.1093/rheumatology/keu138
29. Yalcinkaya F, Ozcakar ZB, Tanyildiz M, Elhan AH (2011) Familial Mediterranean fever in small children in Turkey. Clin Exp Rheumatol 29:87–90
30. Dinarello CA, van der Meer JWM (2013) Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 25:469–484